# US 2005/0239803 A1 · Method for the preparation of 5-methylpyrazine-2-carboxylic acid-4-oxide and its salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239803 A1
- Document ID: US20050239803A1
- Status: Published application
- Kind: A1
- Application number: 10/829,886
- Filed: 2004-04-22
- Published: 2005-10-27
- Earliest claimed: 2004-04-22
- Assignees: ISP Investments Inc.
- Inventors: Jonathan Caudill; Mark Cooney; Satish Nigam
- Web page: https://patentgrep.com/patent/US20050239803A1

## CPC

- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods for the preparation of pharmaceutically acceptable salts of 5-methylpyrazine-carboxylic acid-4-oxide by using the oxidizing agent OXONE® for the N-oxidation of C1-4 methylpyrazinecarboxylic acid esters. The pharmaceutically acceptable salts are then formed by the saponification of the esters followed by alcohol precipitation.

## Claims

### Claim 1

A method for the preparation of a 5-methylpyrazinecarboxylic acid ester-4-oxide comprising:
reacting 5-methylpyrazinecarboxylic acid with a C1-4 alcohol in the presence of the ion exchange resin AMBERLYST® to obtain the ester of 5-methylpyrazine-carboxylic acid; and
oxidizing the 5-methylpyrazinecarboxylic ester in the presence of OXONE® in a halogenated solvent to obtain the isolated ester oxide.

### Claim 2

A method for the preparation of the pharmaceutically acceptable inorganic salts of 5-methylpyrazinecarboxylic acid-4-oxide comprising oxidizing an ester of 5-methylpyrazine-carboxylic acid-4-oxide in a biphasic system consisting of a halogenated solvent and an aqueous solution of OXONE®.

### Claim 3

A method for the preparation of the sodium or potassium salts of 5-methylpyrazine-carboxylic acid-4-oxide comprising: reacting 5-methylpyrazinecarboxylic acid esters with sodium or potassium silanolates in a solvent.

### Claim 4 (depends on 3)

The method of claim 3 wherein said solvent is diethyl ether or 2,3,4,5-tetrahydro-9-furan.

### Claim 5

A method for the preparation of a pharmaceutically acceptable inorganic salt of a 5-methylpyrazinecarboxylic acid-4-oxide having the formula I
wherein
M is an inorganic salt selected from the group consisting of Na, K, Mg and Ca, comprising the steps of:
reacting 5-methylpyrazinecarboxylic acid having the formula II
wherein
R is H or an alkyl group having from 1 to 4 carbon atoms, with a C1-4 alcohol in the presence of AMBERLYST® to obtain an ester of the formula III
wherein
R is H or C1-4 alkyl;
oxidizing the ester of formula III in a biphasic system consisting of a halogenated solvent and an aqueous solution of OXONE® to obtain an oxidation product; and
saponificating the oxidation product to obtain the salt of formula I.

### Claim 6

A method for the preparation of a pharmaceutically acceptable inorganic salt of a 5-methylpyrazinecarboxylic acid having the formula I
wherein:
M is selected from the group consisting of Na, K, Mg and Ca, comprising the steps of:
heating 5-methylpyrazinecarboxylic acid in a halogenated solvent in the presence of 20 to 40% w/w mineral acid selected from the group consisting of sulfuric acid and hydrochloric acid or AMBERLYST® and 20 to 25% w/w of an aqueous-solution of OXONE® to obtain a solution;
stirring the solution until the reaction is complete;
separating the aqueous layer and extracting it with a solvent to obtain the ester oxide of 5-methylpyrazinecarboxylic acid;
drying said ester oxide;
saponifying said ester oxide;
precipitating a salt of said ester oxide by the addition of a pharmaceutically acceptable alcohol selected from the group consisting of ethanol, isopropanol and denatured alcohol;
collecting said salt by filtration;
washing said salt with alcohol; and
drying said salt under vacuum.

### Claim 7 (depends on 6)

The pharmaceutically acceptable inorganic salt prepared by the method of claim 6.
